Filings
| Filing | Date | Type | Filed with |
|---|
| Appendix 3Y Maria Rivas | Nov 4, 2026 | Other filings | ASX |
|---|
| Telix Capital Markets Day Presentation November 2026 | Nov 3, 2026 | Other filings | ASX |
|---|
| Change of Director's Interest Notice - Marie McDonald | Nov 3, 2026 | Ownership change notice | ASX |
|---|
| Notification regarding unquoted securities - TLX | Nov 3, 2026 | Other filings | ASX |
|---|
| Cancellation of Appendix 2A | Nov 2, 2026 | Financing | ASX |
|---|
| Telix Notice of General Meeting, Proxy Form and Online Guide | Oct 29, 2026 | Meeting notice | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 29, 2026 | Current report | SEC |
|---|
| Application for quotation of securities - TLX | Oct 28, 2026 | Financing | ASX |
|---|
| Appendix 3Y Dr Christian Behrenbruch | Oct 26, 2026 | Other filings | ASX |
|---|
| Appendix 3Y William Jellison | Oct 25, 2026 | Other filings | ASX |
|---|
| Appendix 3Y Change in Director Interest - D Gill | Oct 25, 2026 | Management or board change | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 20, 2026 | Current report | SEC |
|---|
| Telix Reports Third Quarter 2026 Financial Performance | Oct 20, 2026 | Quarterly report | ASX |
|---|
| Telix Reports Third Quarter 2026 Financial Performance | Oct 20, 2026 | Quarterly report | ASX |
|---|
| Notification of cessation of securities - TLX | Oct 4, 2026 | Financing | ASX |
|---|
| Notification regarding unquoted securities - TLX | Oct 4, 2026 | Other filings | ASX |
|---|
| Application for quotation of securities - TLX | Oct 4, 2026 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 29, 2026 | Current report | SEC |
|---|
| FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging | Sep 29, 2026 | Operations update | ASX |
|---|
| Change in substantial holding | Sep 25, 2026 | Ownership change notice | ASX |
|---|
| Appendix 3Y Change in Director Interest-D Gill | Sep 25, 2026 | Management or board change | ASX |
|---|
| Application for quotation of securities - TLX | Sep 25, 2026 | Financing | ASX |
|---|
| Grant of waivers of Listing Rule 7.3.4 | Sep 21, 2026 | Acquisition or disposal | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 21, 2026 | Current report | SEC |
|---|
| Telix and ITM Join Forces to Create Radiopharma Powerhouse | Sep 20, 2026 | Other filings | ASX |
|---|
| Telix and ITM Join Forces to Create Radiopharma Powerhouse | Sep 20, 2026 | Acquisition or disposal | ASX |
|---|
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 14, 2026 | Current report | SEC |
|---|
| Application for quotation of securities - TLX | Sep 14, 2026 | Financing | ASX |
|---|
| FDA Approves Telix Brain Cancer Imaging Drug Pixclara | Sep 13, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 1, 2026 | Current report | SEC |
|---|
| Telix Completes Enrollment in Phase 3 BiPASS Study | Sep 1, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 31, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 19, 2026 | Current report | SEC |
|---|
| Telix HY26 Results Presentation | Aug 19, 2026 | Other filings | ASX |
|---|
| Telix HY26 Results Announcement | Aug 19, 2026 | Results | ASX |
|---|
| Telix HY26 Appendix 4D and Interim Report | Aug 19, 2026 | Interim report | ASX |
|---|
| Telix H1 2026 Results - Investor Webcast Notification | Jul 30, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 21, 2026 | Current report | SEC |
|---|
| Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress | Jul 20, 2026 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 2, 2026 | Current report | SEC |
|---|
| FDA Alignment to Advance ProstACT Global Phase 3 Trial | Jul 1, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | May 21, 2026 | Current report | SEC |
|---|
| 3 · Initial statement of ownership | May 18, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | May 18, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | May 18, 2026 | Insider trade | SEC |
|---|
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
|---|
| UPLOAD · Letter from the SEC | Apr 23, 2026 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 22, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 21, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 20, 2026 | Current report | SEC |
|---|
| CORRESP · Letter to the SEC | Apr 17, 2026 | Other filings | SEC |
|---|
| Telix Successfully Prices Upsized US$600M Convertible Bonds | Apr 14, 2026 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 14, 2026 | Current report | SEC |
|---|
| Telix Investor Presentation April 2026 | Apr 14, 2026 | Other filings | ASX |
|---|
| Telix Refinances Convertible Bonds | Apr 14, 2026 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 14, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 13, 2026 | Current report | SEC |
|---|
| Telix and Regeneron Announce Radiopharma Collaboration | Apr 12, 2026 | Operations update | ASX |
|---|
| FDA Accepts NDA for TLX101-Px (Pixclara) | Apr 9, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 9, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 8, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 7, 2026 | Current report | SEC |
|---|
| Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement | Apr 6, 2026 | Results | ASX |
|---|
| UPLOAD · Letter from the SEC | Apr 3, 2026 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 2, 2026 | Current report | SEC |
|---|
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 20-F/A · Annual report, amended | Mar 20, 2026 | Annual report | SEC |
|---|
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 16, 2026 | Current report | SEC |
|---|
| Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging | Mar 15, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Mar 10, 2026 | Current report | SEC |
|---|
| ProstACT Global Phase 3 (Part 1) Results Presentation | Mar 9, 2026 | Other filings | ASX |
|---|
| ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives | Mar 9, 2026 | Other filings | ASX |
|---|
| F-3ASR | Feb 20, 2026 | Other filings | SEC |
|---|
| 2025 Full Year Results Presentation | Feb 19, 2026 | Results | ASX |
|---|
| Appendix 4E and 2025 Annual Report | Feb 19, 2026 | Annual report | ASX |
|---|
| 2025 Full Year Results Announcement | Feb 19, 2026 | Results | ASX |
|---|
| 20-F · Annual report | Feb 19, 2026 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 19, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 18, 2026 | Current report | SEC |
|---|
| Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging | Feb 17, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 2, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 20, 2026 | Current report | SEC |
|---|
| Telix Achieves FY25 Guidance - US$804M, Q4 Growth | Jan 20, 2026 | Results | ASX |
|---|
| Chinese NMPA Accepts New Drug Application for Illuccix | Jan 19, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Jan 12, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 22, 2025 | Current report | SEC |
|---|
| Precision Medicine Portfolio Update | Dec 21, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 17, 2025 | Current report | SEC |
|---|
| ProstACT Global Study Status | Dec 17, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 8, 2025 | Current report | SEC |
|---|
| 1st Patient Dosed in ProstACT Global Randomized Tx Expansion | Dec 7, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 14, 2025 | Current report | SEC |
|---|
| Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded | Oct 14, 2025 | Guidance | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 23, 2025 | Current report | SEC |
|---|
| CMS Grants Transitional Pass-Through Status for Gozellix | Sep 22, 2025 | Operations update | ASX |
|---|
| Telix and FDA Agree Resubmission Pathway for Pixclara NDA | Sep 8, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 8, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Aug 28, 2025 | Current report | SEC |
|---|
| Telix Provides Regulatory Update on TLX250-CDx | Aug 27, 2025 | Legal or regulatory action | ASX |
|---|
| Telix H1 2025 Results Announcement | Aug 20, 2025 | Results | ASX |
|---|
| Telix H1 2025 Results Presentation | Aug 20, 2025 | Results | ASX |
|---|
| Telix H1 2025 Appendix 4D and Interim Report | Aug 20, 2025 | Interim report | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 20, 2025 | Current report | SEC |
|---|
| Historical Financials in USD and H12025 OPEX (Unaudited) | Aug 4, 2025 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 22, 2025 | Current report | SEC |
|---|
| Telix Reports US$204M Q2 Revenue, Up 63% YOY | Jul 22, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 9, 2025 | Current report | SEC |
|---|
| Gozellix Receives Permanent HCPCS Code | Jul 9, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Jun 11, 2025 | Current report | SEC |
|---|
| Telix Investor Day Presentation | Jun 11, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | May 21, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 28, 2025 | Current report | SEC |
|---|
| Telix Provides Regulatory Update on TLX101-CDx | Apr 27, 2025 | Legal or regulatory action | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 22, 2025 | Current report | SEC |
|---|
| Telix Reports US$186M Q1 Revenue, Up 62% YOY | Apr 22, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 17, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 17, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 7, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 3, 2025 | Current report | SEC |
|---|
| FDA Approves New Prostate Cancer Imaging Agent Gozellix | Mar 20, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Mar 20, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 18, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 12, 2025 | Current report | SEC |
|---|
| Telix Completes FAP-Targeting Theranostic Acquisition | Mar 11, 2025 | Acquisition or disposal | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 26, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 26, 2025 | Current report | SEC |
|---|
| FDA accepts BLA and grants priority review for Zircaix | Feb 25, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 25, 2025 | Current report | SEC |
|---|
| Telix Announces Change in Reporting Currency to USD | Feb 24, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 24, 2025 | Current report | SEC |
|---|
| 20-F · Annual report | Feb 24, 2025 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 21, 2025 | Current report | SEC |
|---|
| 2024 Full Year Results Presentation | Feb 20, 2025 | Results | ASX |
|---|
| 2024 Full Year Results Announcement | Feb 20, 2025 | Results | ASX |
|---|
| Appendix 4E and 2024 Annual Report | Feb 20, 2025 | Annual report | ASX |
|---|
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
|---|
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 13, 2025 | Current report | SEC |
|---|
| Illuccix Approved in the United Kingdom | Feb 12, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Jan 31, 2025 | Current report | SEC |
|---|
| Telix Completes Acquisition of Tx Assets, Biologics Platform | Jan 30, 2025 | Acquisition or disposal | ASX |
|---|
| Telix Completes Acquisition of RLS (USA) Inc | Jan 27, 2025 | Acquisition or disposal | ASX |
|---|
| 6-K · Report of a foreign issuer | Jan 27, 2025 | Current report | SEC |
|---|
| Illuccix Receives European Approval | Jan 16, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Jan 16, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 13, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 13, 2025 | Current report | SEC |
|---|
| Telix JP Morgan Healthcare Conference 2025 Presentation | Jan 13, 2025 | Other filings | ASX |
|---|
| Telix Exceeds FY24 Guidance with US$142M Q4 Revenue | Jan 13, 2025 | Guidance | ASX |
|---|
| Presentation to Accompany Biologics Platform Acquisition | Jan 12, 2025 | Acquisition or disposal | ASX |
|---|
| TLX to Acquire Next-Gen Therapeutics and Biologics Platform | Jan 12, 2025 | Acquisition or disposal | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 30, 2024 | Current report | SEC |
|---|
| S-8 · Registration statement for employee plans | Dec 19, 2024 | Offer document | SEC |
|---|
| SEC STAFF LETTER | Nov 21, 2024 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 19, 2024 | Current report | SEC |
|---|
| Presentation to Accompany FAP-Targeting Acquisition | Nov 18, 2024 | Acquisition or disposal | ASX |
|---|
| Telix Adds FAP-Targeting Theranostic Candidates to Pipeline | Nov 18, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 14, 2024 | Current report | SEC |
|---|
| EFFECT · Notice that a registration is effective | Nov 13, 2024 | Other filings | SEC |
|---|
| SEC STAFF ACTION | Nov 12, 2024 | Other filings | SEC |
|---|
| CERT · Exchange's certificate of listing | Nov 12, 2024 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | Nov 12, 2024 | Other filings | SEC |
|---|
| CMS payment improvement decision for radiopharma diagnostics | Nov 3, 2024 | Operations update | ASX |
|---|
| SEC STAFF LETTER | Oct 30, 2024 | Other filings | SEC |
|---|
| 20FR12B/A | Oct 29, 2024 | Other filings | SEC |
|---|
| FDA accepts NDA and grants priority review for Pixclara | Oct 23, 2024 | Operations update | ASX |
|---|
| Telix Files Form 20-F Registration Statement for Nasdaq ADS | Oct 17, 2024 | Other filings | ASX |
|---|
| F-6 | Oct 17, 2024 | Other filings | SEC |
|---|
| CORRESP · Letter to the SEC | Oct 17, 2024 | Other filings | SEC |
|---|
| 20FR12B | Oct 17, 2024 | Other filings | SEC |
|---|
| Telix Q3 2024 Revenue and Business Update | Oct 17, 2024 | Results | ASX |
|---|
| UPLOAD · Letter from the SEC | Oct 10, 2024 | Other filings | SEC |
|---|
| Telix to Acquire RLS for US Manufacturing and Distribution | Sep 22, 2024 | Acquisition or disposal | ASX |
|---|
| DRS · Draft registration statement | Sep 13, 2024 | Offer document | SEC |
|---|
| Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent | Aug 27, 2024 | Operations update | ASX |
|---|
| Telix 1H 2024 Results Release | Aug 22, 2024 | Results | ASX |
|---|
| Telix 1H 2024 Results Presentation | Aug 22, 2024 | Other filings | ASX |
|---|
| Telix 1H 2024 Appendix 4D and Interim Report | Aug 22, 2024 | Interim report | ASX |
|---|
| Telix Completes A$650 Million of Convertible Bonds | Jul 30, 2024 | Financing | ASX |
|---|
| Convertible Bond Cleansing Notice | Jul 29, 2024 | Financing | ASX |
|---|
| Telix Successfully Prices A$650M Convertible Bonds | Jul 23, 2024 | Financing | ASX |
|---|
| Telix Announces A$600 Million Convertible Bonds Offering | Jul 23, 2024 | Financing | ASX |
|---|
| Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade | Jul 17, 2024 | Results | ASX |
|---|
| CMS proposes payment improvement for radiopharma diagnostics | Jul 11, 2024 | Operations update | ASX |
|---|
| RW · Request to withdraw a registration | Jun 14, 2024 | Other filings | SEC |
|---|
| RW · Request to withdraw a registration | Jun 14, 2024 | Other filings | SEC |
|---|
| Telix Elects to Withdraw from Proposed U.S. Listing | Jun 13, 2024 | Other filings | ASX |
|---|
| Trading Halt | Jun 12, 2024 | Trading halt or suspension | ASX |
|---|
| 8-A12B · Registration of shares for listing on an exchange | Jun 10, 2024 | Other filings | SEC |
|---|
| Telix Launches Proposed US IPO | Jun 5, 2024 | Offer document | ASX |
|---|
| F-1/A · Registration statement, amended | Jun 5, 2024 | Offer document | SEC |
|---|
| Telix Completes TLX250-CDx (Zircaix) BLA Submission | Jun 2, 2024 | Operations update | ASX |
|---|
This page holds 200 of 441 filings.
All of its filings on SEC EDGAR